OXBDF (Oxford BioMedica) GF Value Rank: 6 (As of Jul. 06, 2026) — 20% Above Median


OXBDF Oxford BioMedica PLC OXBDF
71 GF Score
Price $7.93
GF Value $7.11
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica GF Value Rank?

Oxford BioMedica OXBDF 71 GF Value Rank is 6 as of Jul. 06, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $7.11 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Oxford BioMedica has the GF Value Rank of 6.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Oxford BioMedica GF Value Rank Related Terms

OXBDF vs VRTX, REGN, ALNY: GF Value Rank Comparison

For the Biotechnology subindustry, Oxford BioMedica's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's GF Value Rank falls into.


OXBDF
71GF Score
Oxford BioMedica PLC OXBDF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 6 mean?
Oxford BioMedica (OXBDF) has a GF Value Rank of 6 as of Jul. 06, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Oxford BioMedica and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Oxford BioMedica's GF Value Rank has ranged from 1.00 to 10.00.
Is Oxford BioMedica's GF Value Rank too high?
Oxford BioMedica's current GF Value Rank of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's GF Value Rank compare to VRTX and REGN?
Oxford BioMedica's GF Value Rank of 6 can be compared against companies in the Biotechnology industry. Historically, Oxford BioMedica's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current GF Value Rank is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.11, compared to a current price of $7.93 — trading 11.5% above its estimated fair value. The current GF Value Rank is 6, which is 20% above median its 10-year median of 5.00. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current GF Value Rank is 6 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.93 is trading 11.5% above its estimated GF Value™ of $7.11. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • GF Value Rank: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: $7.11 vs. price of $7.93 (11.5% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score

Get the complete analysis for OXBDF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.93
Price
$7.11
GF Value